ArticlePolymer2026
Biodegradable poly(ε-caprolactone)/poly(silyl fumarate) shape memory scaffolds.
Article in Polymer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Biodegradable shape memory scaffolds have the unique potential to heal irregularly shaped craniomaxillofacial (CMF) defects through conformal 'self-fitting'. These have been previously prepared from poly(ε-caprolactone) diacrylate (PCL-DA), but the slow biodegradation rate of PCL is expected to limit neotissue formation. Subsequently, telechelic siloxane macromers polydimethylsiloxane-dimethacrylate (PDMS-DMA) and polymethylhydrosiloxane-DMA (PMHS-DMA) were combined with PCL-DA at varying weight (wt)% ratios, resulting in PCL/PDMS and PCL/PMHS co-network scaffolds with accelerated degradation rates owing to phase separation that increased water uptake. Still, these siloxane macromers lack a hydrolytically unstable backbone thus limiting degradation. Herein, poly(silyl fumarate) (PSF) was synthesized as a hybrid siloxane macromer with a hydrolytically unstable backbone as well as interchain crosslinkability. PCL/PSF scaffolds were prepared at 90:10, 75:25, 60:40, and 50:50 wt% of PCL-DA to PSF via solvent-casting particulate leaching (SCPL) with a fused salt template. Despite a reduction in PCL crystallinity (i.e., switching segments) with 40 and 50 wt% PSF, all scaffolds maintained excellent shape memory behavior. PCL/PSF scaffolds with 10 and 25 wt% PSF also maintained the modulus of the PCL-only scaffold as well as the corresponding PCL/PDMS and PCL/PMHS scaffolds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.